Funding Opportunity RFA-AT-25-002 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites investigators currently funded through the NIH Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone (IMPROVE) Initiative to develop applications to test the feasibility of complementary and integrative approaches with psychological and/or physical inputs (often called mind and body interventions) to promote healthy pregnancies and enhance maternal health outcomes. Currently funded IMPROVE investigators- particularly the Maternal Health Centers of Excellence- are encouraged to partner with investigators with complementary and integrative health expertise. Eligibility is limited to currently funded investigators of the IMPROVE initiative. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial on a mind and body intervention to enhance maternal health. It is expected that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficac

Funding Opportunity RFA-NR-25-004 from the NIH Guide for Grants and Contracts. Research shows that intersecting systems of privilege and oppression produce and sustain wide and unjust variations in health. The Axes Initiative will support research to understand health at the intersections of social statuses such as race, ethnicity, socioeconomic status, sexual orientation, and ability, by examining contributions of social and other determinants of health.

Funding Opportunity RFA-AT-25-003 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: (1) support the efforts by R15-eligible Principal Investigators (PIs) to conduct rigorous basic and/or mechanistic pain research projects; (2) promote integrated, interdisciplinary research partnerships between R15-eligible PIs and additional investigators from U.S. domestic institutions, and (3) enhance the pain research environment at the R15-eligible institution for health professional trainees or undergraduate and/or graduate students by actively engaging them in the proposed pain research projects.

Funding Opportunity PAS-25-102 from the NIH Guide for Grants and Contracts. This Notice of Funding Announcement (NOFO) encourages the submission ofpilot and feasibilityclinical trialsconducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this NOFO should have clearly described aims and objectives and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health.Preliminary data regarding intervention efficacy are not required.

Funding Opportunity PAR-25-377 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and multi-disciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and health care disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos. Multi-disciplinary research teams would be expected to meaningfully collaborate with key partners that must include at least one PI or MPI from institutions in Latin America.

Funding Opportunity PAS-25-073 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

Funding Opportunity PAR-25-048 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.

Notice NOT-LM-24-008 from the NIH Guide for Grants and Contracts

Notice NOT-RM-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-055 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-042 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-363 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PA-23-XXX.

Funding Opportunity PAR-25-335 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.

Funding Opportunity RFA-RM-24-013 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites applications from eligible organizations to establish the New Approach Methodologies (NAMs) Data Hub and Coordinating Center (NDHCC) for the NIH Common Fund Complement Animal Research In Experimentation (Complement-ARIE) program. The goal of Complement-ARIE is to implement better models for understanding human health and disease outcomes across diverse populations that complement traditional models and make biomedical research more efficient and effective. The award made through this announcement will support Complement-ARIE by providing a centralized data hub, building a searchable repository for various NAMs data types, establishing standards for data reporting and model credibility, developing and implementing an Integrated Testing Strategies (ITS), developing strategies for interoperability, sustainability data reuse, and developing tools for data analytics, dissemination, and sharing. The awardee will also serve as the coordinating center for the overall Complement-ARIE program.

Notice NOT-CA-25-030 from the NIH Guide for Grants and Contracts

Notice NOT-NR-25-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-324 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for longer term support to ESIs, the NCI intends to offer flexibility and opportunity for creativity and innovation and additional time to successfully launch their careers and to become more established before having to submit renewal applications (NOT-CA-18-037). The objective of the NCI's ESI MERIT Award is to allow eligible investigators the opportunity to obtain up to 7 years of support in two segments:

Funding Opportunity PAR-25-343 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.

Funding Opportunity RFA-DC-25-005 from the NIH Guide for Grants and Contracts. This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Ultimately, research supported in response to this RFA is to encourage technologies that allow, for example, structures such as hair cells, otoliths, membranes, ions, and vasculature to be viewed in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multi-disciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in animals, but not non-mammalian species, may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans.

Funding Opportunity RFA-DC-25-003 from the NIH Guide for Grants and Contracts. This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this RFA is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans must be proposed to develop,advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans.